Towards optimizing cefepime/tazobactam (WCK 4282) exposure to achieve efficacy against piperacillin/tazobactam-resistant ESBL infections: dose recommendations for various renal functions, including intermittent haemodialysis, in healthy individuals

Author – Anouk E Muller, Brenda C M De Winter, Birgit C P Koch

Journal Name – Journal of Antimicrobial Chemotherapy

Citation – Volume 79, Issue 5, May 2024, Pages 1093–1100

Ensuring robustness in the quality of antibiotic susceptibility test discs for four novel antibiotics

Author – Vinod K. Ahirrao, Rajiv A. Jadhav, Suyog N. Vaidya, Sachin S. Bhagwat, Ravindra D. Yeole, Mahesh V. Patel

Journal Name – Biomedical Chromatography

Citation – Volume 36, Issue 6, June 2022

Hg (OAc) 2/1, 2, 3-triazole-mediated efficient synthesis of Tazobactam

Author – Yasinalli Tamboli, Amit P Pund, Jaydeo T Kilbile, Arvind Y Merwade

Journal Name – Chemical Papers

Impact Factor – 2.14

Citation – AOP, 2022 

Antimicrobial Activity of High-Dose Cefepime-tazobactam (WCK 4282) against a Large Collection of Gram-negative Organisms Collected Worldwide in 2018 and 2019

Author – Helio S.Sader, Cecilia G.Carvalhaes, Rodrigo E.Mendes, Mariana Castanheira

Journal Name – International Journal of Infectious Diseases

Impact Factor – 1.278

Citation – 2022, 116, 306-312 

Cefepime/tazobactam compared with other tazobactam combinations against problem Gram-negative bacteria

Author – Shazad Mushtaq, Paolo Garello, Anna Vickers, Neil Woodford, David M Livermore

Journal Name – International Journal of Antimicrobial Agents

Impact Factor – 4.621

Citation – 2021, 57(5), May, 106318 

In Vivo Activity of WCK 4282 (High-Dose Cefepime/Tazobactam) against Serine-β-Lactamase-Producing Enterobacterales and Pseudomonas aeruginosa in the Neutropenic Murine Lung Infection Model

Author – Maxwell J. Lasko, Kamilia Abdelraouf, David P. Nicolau

Journal Name – Antimicrobial Agents and Chemotherapy

Impact Factor – 4.904

Citation – 2021, 65(4), e02193-20 

In Vivo Activity of WCK 4282 (High-Dose Cefepime/Tazobactam) against Serine-β-Lactamase-Producing Enterobacterales and Pseudomonas aeruginosa in the Neutropenic Murine thigh Infection Model

Author – Christian M Gill, Kamilia Abdelraouf, David P Nicolau

Journal Name – Journal of Antimicrobial Chemotherapy

Impact Factor – 5.439

Citation – 2021, 76(4), 993-1000 

Single-Center Investigation of the Pharmacokinetics of WCK 4282 (Cefepime-Tazobactam Combination) in Renal Impairment

Author – Preston, Richard A.; Mamikonyan, Grigor; Mastim, Mushtaque; Garg, Dyal; Kemper, Christopher J.; Xu, Allan; Yeole, Ravindra; Chavan, Rajesh; Friedland, H. David; Bhatia, Ashima

Journal Name – Antimicrobial Agents and Chemotherapy

Impact Factor – 4.921

Citation – 2019, 63(10), e00873-19 

Antimicrobial Susceptibility Testing Quality Control of β-lactam/ β-lactamase Inhibitor Combination Agents in Clinical Development

Author – Ayuen Lual, Heena Shah, Jane E. Ambler, Suyog Vaidya, Brian Beck

Journal Name – CLSI AST News Update

Citation – 2019, 4(1), 20-21 

Potential of high-dose cefepime/tazobactam against multiresistant Gram-negative pathogens

Author – David M Livermore, Shazad Mushtaq, Marina Warner, Simon J Turner, Neil Woodford

Journal Name – Journal of Antimicrobial Chemotherapy

Impact Factor – 5.113

Citation – 2018, 73(1), 126–133 

Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Cefepime in an In Vitro Infection Model

Author – Brian D. VanScoy, David Tenero, Simon Turner, David M. Livermore, Jennifer McCauley, Haley Conde, Sujata M. Bhavnani, Christopher M. Rubino, Paul G. Ambrose

Journal Name – Antimicrobial Agents and Chemotherapy

Impact Factor – 4.548

Citation – 2017, 61(12), e01052-17 

Determination of Disk Diffusion and MIC Quality Control Guidelines for High-Dose Cefepime-Tazobactam (WCK 4282), a Novel Antibacterial Combination Consisting of a β-Lactamase Inhibitor and a Fourth-Generation Cephalosporin

Author – Stefan Riedel, Michael D Huband, Helio S Sader, Robert K Flamm, Ronald N Jones

Journal Name – Journal of Clinical Microbiology

Impact Factor – 4.054

Citation – 2017, 55(10), 3130-3134 

Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014

Author – Sader, Helio S.; Castanheira, Mariana; Mendes, Rodrigo E.; Flamm, Robert K.; Jones, Ronald N

Journal Name – Antimicrobial Agents and Chemotherapy

Impact Factor – 4.548

Citation – 2017, 61(4), e02409-16 

Enhanced activity of cefepime-tazobactam (WCK 4282) against KPC-producing Enterobacteriaceae when tested in media supplemented with human serum or sodium chloride

Author – Mariana Castanheira, Leonard R.Duncan, Paul R.Rhomberg, Helio S.Sader

Journal Name – Diagnostic Microbiology and Infectious Disease

Impact Factor – 2.341

Citation – 2017, 89(4), 305-309

Pharmacodynamics of Cefepime Combined with Tazobactam against Clinically Relevant Enterobacteriaceae in a Neutropenic Mouse Thigh Model

Author – Maria J. Melchers, Anita C. van Mil, Claudia Lagarde, Jan den Hartigh, Johan W. Mouton

Journal Name – Antimicrobial Agents and Chemotherapy

Impact Factor – 4.548

Citation – 2017, 61(9), e00267-17